Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of astrovirus-associated gastroenteritis among hospitalized pediatric patients in Asia: A systematic review and meta-analysis.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same author

Prevalence of sapovirus infection among hospitalized pediatric patients in Asia: A systematic review and meta-analysis.

World journal of virology·2026
Same author

Microplastics: an emerging environmental contaminant in surface water bodies of Indore, Central India.

Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering·2025
Same author

Thermal influence on development and morphological traits of Aedes aegypti in central India and its relevance to climate change.

Parasites & vectors·2025
Same author

Micro/nanoplastics and human health: A review of the evidence, consequences, and toxicity assessment.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2025
Same author

The evolving landscape of Norovirus GII genotypes in Asia: A systematic review and meta-analysis.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2025

Related Experiment Video

Updated: May 2, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K

Operationalizing Access for Chimeric Antigen Receptor T cell Therapies: A Cross-functional Perspective.

Surya Singh1, Carol Greulich2, Ariel Perez3

  • 1InformedDNA, St. Petersburg, FL.

Mayo Clinic Proceedings. Innovations, Quality & Outcomes
|January 5, 2026
PubMed
Summary

Timely chimeric antigen receptor T cell (CAR T) infusions improve treatment efficacy and reduce mortality. Addressing healthcare infrastructure, complex processes, and reimbursement issues is crucial for faster patient access to CAR T therapy.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.8K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.6K

Related Experiment Videos

Last Updated: May 2, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.8K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.6K

Area of Science:

  • Oncology
  • Immunotherapy
  • Health Services Research

Background:

  • Chimeric antigen receptor T cell (CAR T) therapy offers improved efficacy with timely infusions.
  • Treatment delays are linked to increased mortality rates in CAR T therapy.
  • Existing healthcare infrastructure, complex treatment pathways, and reimbursement challenges hinder timely patient access.

Purpose of the Study:

  • To identify operational barriers contributing to CAR T treatment delays.
  • To propose potential solutions for improving timely patient access to CAR T therapy.
  • To foster cross-functional cooperation among stakeholders.

Main Methods:

  • Convened an expert panel of 6 advisors (3 from transplant centers, 3 from payer organizations).
  • Identified operational barriers and potential solutions through expert discussion.
  • Focused on treatment center certification, clinical criteria alignment, and financial arrangements.

Main Results:

  • Opportunities exist to expand treatment capacity by streamlining center certification and fostering collaboration.
  • Aligning clinical criteria can improve clinician understanding and streamline referrals and authorizations.
  • Negotiating financial arrangements, including payer contracts and single-case agreements, is critical and time-consuming.

Conclusions:

  • Addressing operational barriers and fostering collaboration among stakeholders is essential for timely CAR T access.
  • Streamlining processes, aligning criteria, and improving financial negotiations can reduce treatment delays.
  • Mutual recognition of interdependence among stakeholders is key to effective cross-functional cooperation.